Google
EDIT — EDITAS MEDICINE INC (Healthcare >> Biotechnology)
EDIT FAQ
What is EDIT's ROE?
EDITAS MEDICINE INC reports a Return on Equity (ROE) of -2,471.73%.
What is EDIT's dividend yield?
EDITAS MEDICINE INC offers a dividend yield of 0.00%.
What is EDIT's Deepscope Quality Score?
Deepscope rates EDIT's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy EDIT?
Deepscope's AI Timing Score for EDIT is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does EDIT belong to?
EDITAS MEDICINE INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 2.78
Price
-0.04
(-1.42%)
Day Change
|
|
|---|
EDIT, the overall quality is not good ( Quality = 38) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 2.78 |
| PBV / Sector |
98.18 / 4.48
|
| Earning Per Share | -0.70 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
9.53 M
|
| Average 1W Daily Value |
11.78 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-04 09:24:23 |
| Symbol | EDIT |
| Name | EDITAS MEDICINE INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 153.46 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 432.76 / 8,483.11 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 11 Hurley Street, Cambridge, MA, United States, 02141
Phone: 617 401 9000
Website: https://www.editasmedicine.com
Employees: 87
Sector: Healthcare >> Biotechnology
Description: Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
